Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case.

Abstract

Primary amebic meningoencephalitis (PAM) is a fulminant central nervous system infection caused by the thermophilic free-living ameba Naegleria fowleri. Few survivals have been documented and adequate treatment is lacking. We report 2 PAM cases, 1 fatal and 1 surviving, treated with the novel antiparasitic agent miltefosine.

• Authors: Jennifer R Cope, Dennis A Conrad, Naiomi Cohen, Manuel Cotilla, Alexandre DaSilva, Jonathan Jackson, Govinda S Visvesvara
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 62 Issue 6 Pg. 774-6 (Mar 15 2016) ISSN: 1537-6591 [Electronic] United States
• PMID: 26679626 (Publication Type: Case Reports, Journal Article)
• Copyright: Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Chemical References

• Antiprotozoal Agents
• Phosphorylcholine
• miltefosine

Topics

• Antiprotozoal Agents (adverse effects, therapeutic use)
• Central Nervous System Protozoal Infections (diagnostic imaging, drug therapy, mortality, parasitology)
• Child
• Fatal Outcome
• Humans
• Male
• Naegleria fowleri (drug effects, isolation & purification)
• Phosphorylcholine (adverse effects, analogs & derivatives, therapeutic use)
• Treatment Outcome